Gland Pharma Limited — Financials & Forensics
Sector: Healthcare · NSE: GLAND · BSE: 543245 · ISIN: INE068V01023
18 Aug 2026
Add GLAND to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹4,401 Cr | ₹3,625 Cr | ₹5,665 Cr | ₹5,617 Cr | ₹6,431 Cr |
| EBITDA | ₹1,510 Cr | ₹1,025 Cr | ₹1,333 Cr | ₹1,269 Cr | ₹1,630 Cr |
| EBITDA margin | 34.3% | 28.3% | 23.5% | 22.6% | 25.3% |
| Profit after tax | ₹1,212 Cr | ₹781 Cr | ₹772 Cr | ₹699 Cr | ₹1,027 Cr |
Deeper analysis
Recent filings by Gland Pharma Limited
-
Q1FY27 Earnings Call Audio recording
10 Aug 2026 · General Update
-
Schedule of Investor Meets
10 Aug 2026 · General Update
-
Investor Presentation
10 Aug 2026 · Financial Results
-
Press Release
10 Aug 2026 · Financial Results
-
Outcome of Board Meeting
10 Aug 2026 · Financial Results
Never miss a filing again
About Gland Pharma Limited on Indian Stock Alerts
Indian Stock Alerts tracks Gland Pharma Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.